Welcome to our dedicated page for Ambiq Micro SEC filings (Ticker: AMBQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ambiq Micro, Inc. filings document the public-company record for a fabless semiconductor issuer focused on ultra-low-power edge AI chips and software. Its SEC disclosures include S-1 registration materials for common stock offerings, 8-K reports on quarterly and annual financial results, and exchange-listing details for AMBQ common stock on the New York Stock Exchange.
Proxy and current-report filings cover shareholder voting matters, director elections, audit-firm ratification, board composition, executive compensation, equity awards, and other governance subjects. Capital-structure disclosures identify common stock terms and offering-related updates.
Connors Michele Kim reported acquisition or exercise transactions in this Form 4 filing.
Ambiq Micro, Inc. General Counsel Michele Kim Connors received a grant of 32,123 shares of common stock in the form of restricted stock units. Following this award, she holds 61,365 common shares directly. Each RSU represents the right to receive one share upon settlement.
According to the grant terms, 25% of the RSUs will vest on September 1, 2027, and the remaining units will vest in quarterly installments of 1/12 thereafter, conditioned on her continued service under the company’s 2025 Equity Incentive Plan.
Winzeler Jeffrey G reported acquisition or exercise transactions in this Form 4 filing.
Ambiq Micro, Inc. reported that Chief Financial Officer Jeffrey G. Winzeler received an equity grant in the form of 41,728 restricted stock units (RSUs) of common stock. The award has no cash purchase price and is part of his compensation rather than an open-market transaction.
Each RSU represents a right to receive one share of common stock upon settlement. According to the vesting schedule, 25% of the units will vest on September 1, 2027, and the remaining units will vest in equal quarterly installments over the following three years, subject to his continuous service under the 2025 Equity Incentive Plan. After this grant, Winzeler directly holds 94,395 shares of Ambiq common stock.
Chen Sean Chihhsiang reported acquisition or exercise transactions in this Form 4 filing.
Ambiq Micro, Inc. President and COO Sean Chihhsiang Chen received an equity grant of 64,246 shares of common stock in the form of restricted stock units. The award was granted at no cash cost and increased his directly held common stock position to 120,275 shares.
Each RSU represents one share of common stock upon settlement. According to the vesting schedule, 25% of the RSUs will vest on September 1, 2027, with the remaining units vesting in equal quarterly installments over the following three years, subject to his continuous service under the company’s 2025 Equity Incentive Plan.
Hanson Scott McLean reported acquisition or exercise transactions in this Form 4 filing.
Ambiq Micro, Inc. director and Chief Technology Officer Scott McLean received a grant of 80,308 restricted stock units of Common Stock as equity compensation. These RSUs vest over time, with 25% vesting on September 1, 2027 and the remainder vesting quarterly thereafter, contingent on continued service. Following this award, McLean directly holds 203,126 shares of Common Stock.
Esaka Fumihide reported acquisition or exercise transactions in this Form 4 filing.
Ambiq Micro, Inc. reported that Chief Executive Officer Fumihide Esaka received a grant of 160,616 restricted stock units (RSUs) of common stock at no cost as equity compensation. Each RSU represents one share upon settlement. Following this award, he directly holds 391,189 shares. The RSUs vest over time: 25% of the shares are scheduled to vest on September 1, 2027, and the remaining shares vest in equal quarterly installments thereafter, contingent on his continued service under the company’s 2025 Equity Incentive Plan.
Ambiq Micro, Inc. develops ultra-low power semiconductor systems-on-chip and software that run AI on edge devices such as wearables, medical and industrial sensors, and smart home products. Its proprietary SPOT platform is designed to cut power consumption two to five times versus conventional designs.
For the year ended December 31, 2025, Ambiq generated net sales of $72.5 million compared with $76.1 million in 2024, and reported a net loss of $36.5 million versus $39.7 million, with an accumulated deficit of $356.7 million as of December 31, 2025. Research and development expenses were $38.5 million in 2025 and $37.2 million in 2024.
The company relies on a fabless model, using TSMC and a small group of packaging and test providers, and is highly dependent on a concentrated set of large customers and distributors. It is shifting away from lower-margin Mainland China business, where sales declined from 50% of net sales in 2024 to 9% in 2025. Ambiq highlights extensive risk factors, including continued losses, customer concentration, supply chain dependence, evolving AI and data privacy regulation, and cybersecurity threats.
Ambiq Micro, Inc. develops ultra-low power semiconductor systems-on-chip and software that run AI on edge devices such as wearables, medical and industrial sensors, and smart home products. Its proprietary SPOT platform is designed to cut power consumption two to five times versus conventional designs.
For the year ended December 31, 2025, Ambiq generated net sales of $72.5 million compared with $76.1 million in 2024, and reported a net loss of $36.5 million versus $39.7 million, with an accumulated deficit of $356.7 million as of December 31, 2025. Research and development expenses were $38.5 million in 2025 and $37.2 million in 2024.
The company relies on a fabless model, using TSMC and a small group of packaging and test providers, and is highly dependent on a concentrated set of large customers and distributors. It is shifting away from lower-margin Mainland China business, where sales declined from 50% of net sales in 2024 to 9% in 2025. Ambiq highlights extensive risk factors, including continued losses, customer concentration, supply chain dependence, evolving AI and data privacy regulation, and cybersecurity threats.
Ambiq Micro, Inc. reported fourth quarter and full year 2025 results showing improving profitability metrics despite slightly lower annual revenue. Full year 2025 net sales were $72.5 million versus $76.1 million in 2024, but GAAP gross margin rose to 44.3% from 31.9%, lifting gross profit to $32.1 million, the highest in company history.
For Q4 2025, net sales reached $20.7 million, the highest quarter of the year, with GAAP gross margin of 42.7% and non-GAAP gross margin of 45.5%. Full year GAAP net loss attributable to common stockholders improved to $36.5 million, while non-GAAP net loss narrowed to $20.9 million.
Ambiq strengthened its balance sheet, ending 2025 with $140.3 million in cash and cash equivalents and converting preferred stock to common following an upsized IPO and follow-on offerings. For Q1 2026, the company guides net sales of $21.0–$22.0 million, non-GAAP gross margin of 44.0–45.0%, and non-GAAP net loss per share between ($0.39) and ($0.33) on 20.38 million weighted average shares.
Ambiq Micro, Inc. reported fourth quarter and full year 2025 results showing improving profitability metrics despite slightly lower annual revenue. Full year 2025 net sales were $72.5 million versus $76.1 million in 2024, but GAAP gross margin rose to 44.3% from 31.9%, lifting gross profit to $32.1 million, the highest in company history.
For Q4 2025, net sales reached $20.7 million, the highest quarter of the year, with GAAP gross margin of 42.7% and non-GAAP gross margin of 45.5%. Full year GAAP net loss attributable to common stockholders improved to $36.5 million, while non-GAAP net loss narrowed to $20.9 million.
Ambiq strengthened its balance sheet, ending 2025 with $140.3 million in cash and cash equivalents and converting preferred stock to common following an upsized IPO and follow-on offerings. For Q1 2026, the company guides net sales of $21.0–$22.0 million, non-GAAP gross margin of 44.0–45.0%, and non-GAAP net loss per share between ($0.39) and ($0.33) on 20.38 million weighted average shares.
Ambiq Micro director-related entity exercises warrants for common shares. Matter Venture Partners Fund I, L.P., for which HSIEH Wen Hsuan exercises sole voting and dispositive control, exercised a warrant for 238,931 shares of Ambiq Micro common stock through a derivative conversion at an exercise price of $12.60 per share. After the transaction, the fund held 633,920 shares of Ambiq Micro common stock indirectly attributable to HSIEH Wen Hsuan.
Ambiq Micro, Inc. Chief Executive Officer and director Esaka Fumihide reported exercising stock options and acquiring additional common shares. On October 7, 2025, a stock option for 53,660 shares with a $5.88 exercise price was exercised, converting into 53,660 shares of common stock at $5.88 per share.
Following this transaction, Esaka Fumihide directly owned 230,573 shares of Ambiq Micro common stock, and the reported option position was reduced to zero. The option had vested over time, with vesting beginning in 2016 and subject to continued service and the issuer’s repurchase rights.
Ambiq Micro, Inc. director Joseph A. Tautges reported a sale of company stock. On January 26, 2026, he sold 7,800 shares of Ambiq Micro common stock at $31 per share in a single open-market transaction. After this sale, he beneficially owns 48,746 common shares, held in direct ownership form.